IL273485A - Enhanced delivery epinephrine and prodrug compositions - Google Patents

Enhanced delivery epinephrine and prodrug compositions

Info

Publication number
IL273485A
IL273485A IL273485A IL27348520A IL273485A IL 273485 A IL273485 A IL 273485A IL 273485 A IL273485 A IL 273485A IL 27348520 A IL27348520 A IL 27348520A IL 273485 A IL273485 A IL 273485A
Authority
IL
Israel
Prior art keywords
epinephrine
enhanced delivery
prodrug compositions
prodrug
compositions
Prior art date
Application number
IL273485A
Other languages
Hebrew (he)
Other versions
IL273485B1 (en
Original Assignee
Aquestive Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/717,859 external-priority patent/US20180125977A1/en
Priority claimed from US15/791,249 external-priority patent/US20180104195A1/en
Application filed by Aquestive Therapeutics Inc filed Critical Aquestive Therapeutics Inc
Publication of IL273485A publication Critical patent/IL273485A/en
Publication of IL273485B1 publication Critical patent/IL273485B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
IL273485A 2017-09-27 2018-09-27 Enhanced delivery epinephrine and prodrug compositions IL273485B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/717,859 US20180125977A1 (en) 2016-05-05 2017-09-27 Enhanced delivery epinephrine compositions
US15/791,249 US20180104195A1 (en) 2016-05-05 2017-10-23 Enhanced delivery epinephrine compositions
PCT/US2018/053042 WO2019067670A1 (en) 2017-09-27 2018-09-27 Enhanced delivery epinephrine and prodrug compositions

Publications (2)

Publication Number Publication Date
IL273485A true IL273485A (en) 2020-05-31
IL273485B1 IL273485B1 (en) 2024-07-01

Family

ID=63858169

Family Applications (1)

Application Number Title Priority Date Filing Date
IL273485A IL273485B1 (en) 2017-09-27 2018-09-27 Enhanced delivery epinephrine and prodrug compositions

Country Status (8)

Country Link
EP (1) EP3687510A1 (en)
JP (2) JP2020535162A (en)
KR (1) KR20200060748A (en)
CN (1) CN111465391A (en)
BR (1) BR112020005948A2 (en)
CA (1) CA3076816A1 (en)
IL (1) IL273485B1 (en)
WO (1) WO2019067670A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109310646A (en) 2016-05-05 2019-02-05 阿奎斯蒂弗医疗股份有限公司 Enhance the adrenaline composition of delivering
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
AU2020373100A1 (en) 2019-11-01 2022-05-19 Aquestive Therapeutics, Inc. Prodrug compositions and methods of treatment
US11571468B2 (en) * 2021-02-01 2023-02-07 Matthias W. Rath Micronutrient combination to reduce blood pressure
US20240016734A1 (en) * 2022-06-14 2024-01-18 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
EP4302751A1 (en) * 2022-07-07 2024-01-10 LTS Lohmann Therapie-Systeme AG Oral thin films with low water activity

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20030143195A1 (en) * 2002-01-30 2003-07-31 Pinsker Judy Senior Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery
US20040096569A1 (en) * 2002-11-15 2004-05-20 Barkalow David G. Edible film products and methods of making same
US20050266085A1 (en) * 2004-05-28 2005-12-01 Warner Kevin S Gelled emulsion and microemulsion formulations for dermal drug delivery
US20070202163A1 (en) * 2005-09-09 2007-08-30 Mutasem Rawas-Qalaji Fast-disintegrating epinephrine tablets for buccal or sublingual administration
IL175338A0 (en) * 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
US20070293582A1 (en) * 2006-06-05 2007-12-20 Malcolm Hill Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
WO2007143674A2 (en) * 2006-06-05 2007-12-13 Verus Pharmaceuticals, Inc. Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
PE20091084A1 (en) * 2007-12-07 2009-07-23 Schering Plough Healthcare PHARMACEUTICAL FORMULATIONS OF PHENYLPHRINE AND COMPOSITIONS FOR TRANSMUCOSAL ABSORPTION
CA2756879A1 (en) * 2009-04-23 2010-10-28 Londonpharma Ltd. Sublingual pharmaceutical composition comprising a neutral oil
MX2012011355A (en) * 2010-03-30 2012-11-30 Phosphagenics Ltd Transdermal delivery patch.
EP2770949A4 (en) * 2011-10-28 2015-07-08 Sung-Yun Kwon Dissolving solid solution perforator patch for migraine treatment
MY191875A (en) * 2012-10-11 2022-07-18 Ix Biopharma Ltd Solid dosage form
US20160051494A1 (en) * 2014-08-21 2016-02-25 Mylan, Inc. Multi-dose medication kit for treating anaphylaxis
CN109310646A (en) * 2016-05-05 2019-02-05 阿奎斯蒂弗医疗股份有限公司 Enhance the adrenaline composition of delivering
EP3452024A1 (en) * 2016-05-05 2019-03-13 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
EP3687508A1 (en) * 2017-09-26 2020-08-05 Aquestive Therapeutics, Inc. Delivery pharmaceutical compositions including permeation enhancers

Also Published As

Publication number Publication date
IL273485B1 (en) 2024-07-01
KR20200060748A (en) 2020-06-01
CN111465391A (en) 2020-07-28
EP3687510A1 (en) 2020-08-05
BR112020005948A2 (en) 2020-12-01
CA3076816A1 (en) 2019-04-04
JP2023159150A (en) 2023-10-31
JP2020535162A (en) 2020-12-03
WO2019067670A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
IL273823A (en) Methods and compositions for topical delivery
HK1258900A1 (en) Delivery methods and compositions
IL262750B (en) Enhanced delivery epinephrine compositions
IL272232A (en) Glp-1 compositions and uses thereof
HUE050894T2 (en) Compositions comprising a combination of ipilimumab and nivolumab
IL271275A (en) Compositions comprising curons and uses thereof
IL273485A (en) Enhanced delivery epinephrine and prodrug compositions
ZA202001044B (en) Drug delivery composition
IL271759B1 (en) Pharmaceutical compositions comprising entrectinib
SG10202112759SA (en) Antimalarial compositions and uses thereof
HK1245113A1 (en) Pharmaceutical compositions and use thereof
IL279877A (en) Ivosidenib forms and pharmaceutical compositions
IL277441A (en) Lfa3 variants and compositions and uses thereof
ZA201903341B (en) Pharmaceutical compositions and uses thereof
GB201812952D0 (en) Compositions and uses thereof
GB201702546D0 (en) Oral delivery compositions
GB201713920D0 (en) Pharmaceutical compositions and uses thereof
GB201711779D0 (en) Delivery
GB201711222D0 (en) Delivery formulation
IL252660B (en) Inverse-freezing compositions and use thereof
GB201707035D0 (en) Drug delivery composition
GB201706968D0 (en) Drug delivery composition
GB201604810D0 (en) Pharmaceutical compositions and uses
GB201602406D0 (en) Compositions and uses thereof
GB201602398D0 (en) Compositions and uses thereof